152 related articles for article (PubMed ID: 24550297)
21. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
22. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis.
Kim Y; Sato K; Asagiri M; Morita I; Soma K; Takayanagi H
J Biol Chem; 2005 Sep; 280(38):32905-13. PubMed ID: 16046394
[TBL] [Abstract][Full Text] [Related]
23. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
24. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
25. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
26. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
[TBL] [Abstract][Full Text] [Related]
28. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway.
Kanematsu M; Yoshimura K; Takaoki M; Sato A
Bone; 2002 Apr; 30(4):553-8. PubMed ID: 11934645
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
[TBL] [Abstract][Full Text] [Related]
30. TNF-alpha expression is transcriptionally regulated by RANK ligand.
Zou W; Amcheslavsky A; Takeshita S; Drissi H; Bar-Shavit Z
J Cell Physiol; 2005 Feb; 202(2):371-8. PubMed ID: 15389596
[TBL] [Abstract][Full Text] [Related]
31. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
32. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo.
Wei CM; Liu Q; Song FM; Lin XX; Su YJ; Xu J; Huang L; Zong SH; Zhao JM
J Cell Physiol; 2018 Jan; 233(1):476-485. PubMed ID: 28294321
[TBL] [Abstract][Full Text] [Related]
33. RANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis.
Chen J; Sun Y; Mao X; Liu Q; Wu H; Chen Y
J Biol Chem; 2010 Nov; 285(47):36315-21. PubMed ID: 20837480
[TBL] [Abstract][Full Text] [Related]
34. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
[TBL] [Abstract][Full Text] [Related]
35. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Li L; Sapkota M; Kim SW; Soh Y
Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
[TBL] [Abstract][Full Text] [Related]
36. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J.
Zhao B; Grimes SN; Li S; Hu X; Ivashkiv LB
J Exp Med; 2012 Feb; 209(2):319-34. PubMed ID: 22249448
[TBL] [Abstract][Full Text] [Related]
37. Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways.
Hsiao HB; Lin H; Wu JB; Lin WC
Osteoporos Int; 2013 May; 24(5):1663-76. PubMed ID: 23143538
[TBL] [Abstract][Full Text] [Related]
38. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
[TBL] [Abstract][Full Text] [Related]
39. Vitamin C-deficiency stimulates osteoclastogenesis with an increase in RANK expression.
Hie M; Tsukamoto I
J Nutr Biochem; 2011 Feb; 22(2):164-71. PubMed ID: 20444587
[TBL] [Abstract][Full Text] [Related]
40. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
